Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

As of December 31, 2024, LAVA had cash, cash equivalents, and investments of $76.6 million, compared to cash, cash equivalents, and investments of $95.6 million as of December 31, 2023. The Company ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

GLP-1 receptor agonists are peptide-based drugs used for managing diabetes and for weight loss, but these treatments have had shortages recently. Now, through a process called in vivo antibody ...

Nicotinic acetylcholine receptors (nAChRs), as nicotine targets ... Correlating cerebrospinal fluid (CSF) nAChR-related proteins (e.g., lynx1 or SLURP-1) with PD progression in ongoing nicotine trials ...

1 Department of Translational Virology ... Use of two separate pattern recognition receptor (PRR) agonists as adjuvants in vaccine formulations has shown to enhance the immune response against the ...

SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and MET overexpression (OverExp) and/or amplification (Amp) following progressive disease (PD ...

Donepezil and memantine AD Capsule that has the combined actions of donepezil and memantine Low appetite; Bruising; Diarrhea; Dizziness; Headache; Nausea; Vomiting Rivastigimine capsule AD; Dementia ...